Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apabetalone (RVX000222) Safety and Biomarkers in Fabry Disease
NCT03228940Phase 2Withdrawn
- Sponsor
- Resverlogix Corp.
- Start
- Nov 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apabetalone in Fabry disease (FD), sponsored by Resverlogix Corp. Primary endpoints: Adverse events at 16 weeks and Changes in clinical laboratory parameters at 12 weeks. Planned start Nov 2022; status: withdrawn.
02
Drugs
apabetalone
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT03228940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03228940.